Oaktree Acquisition Corp. III Life Sciences
OACC
$10.77
$0.010.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.20M | 1.21M | 1.20M | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.20M | 1.21M | 1.20M | -- | -- |
| Operating Income | -1.20M | -1.21M | -1.20M | -- | -- |
| Income Before Tax | 6.75M | 7.02M | 7.29M | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.75 | 7.02 | 7.29 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.75M | 7.02M | 7.29M | -- | -- |
| EBIT | -1.20M | -1.21M | -1.20M | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.27 | 0.29 | 0.30 | -- | -- |
| Normalized Basic EPS | 0.17 | 0.18 | 0.19 | -- | -- |
| EPS Diluted | 0.27 | 0.29 | 0.30 | -- | -- |
| Normalized Diluted EPS | 0.17 | 0.18 | 0.19 | -- | -- |
| Average Basic Shares Outstanding | 98.33M | 98.33M | 98.33M | -- | -- |
| Average Diluted Shares Outstanding | 98.33M | 98.33M | 98.33M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |